Formerly the R&D center of Origincell Technology Group, Shanghai Origincell Medical Technology Inc. was established in 2015. In 2019, with the support of the Origincell and venture capital firms such as Qiming Venture Partners, it focused on the core business of the research and development of tumor immune cell therapy products, and was renamed OriCell Therapeutics in 2021. OriCell Therapeutics is ommitted to developing novel immunotherapies.

Through independent innovation, OriCell has built several patented technology platforms for pharmaceutical R&D based on tumor cell immunotherapy. Achieving a breakthrough in the effectiveness of CAR-T treatment of solid tumors in aspects such as antibody sequence screening & development, tumor immune microenvironment regulation, T cell infiltration and killing ability, and has obtained positive data on safety and effectiveness in the explorative clinical studies. Among them, the exploratory clinical research presented positive data on Ori-C101, a CAR-T product targeting liver cancer, and was shown in ASCO 2021. Result of phase I open-label single arm study of Ori-CAR017, a product targeting relapsed/refractory multiple myeloma was given the opportunity of an oral presentation at the ASCO 2022 conference. OriCell's self-developed bispecific monoclonal antibody(PD-L1/4-1BB) drug YN051 (ATG101) was licensed to Antengene (B.6996) for further development at the price of an initial payment plus milestone totalling 142 million US dollars, and this project has obtained registering clinical trial permission in Australia, the United States and China. 

At present, OriCell Therapeutics boasts of more than 10 cellular drugs and BsAb drugs mainly for the treatment of solid tumors, and focuses on liver cancer, ovarian cancer, gastric cancer, cervical cancer, non-small cell lung cancer, multiple myeloma, etc. OriCell Therapeutics has been upholding the enterprise vision of "becoming the driving force of innovation and development of the world's tumor immunotherapy treatments", endeavoring constantly explore and develop innovative cell immunotherapy drugs for tumors with good curative effect, differentiation, affordable costs, and progressing continuously for establishing a new phase in "innovative drugs made in China".